Research programme: 17-beta hydroxysteroid dehydrogenase type 1 inhibitors - ElexoPharma
Latest Information Update: 04 Jul 2016
At a glance
- Originator ElexoPharm GmbH
- Mechanism of Action Hydroxysteroid dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Endometriosis
Most Recent Events
- 04 Jul 2016 Preclinical trials in Endometriosis in Germany (unspecified route)